Suchergebnisse - "rucaparib"

PubPharm (16)

1

Method of the synthesis of selenium homolog of rucaparib

enthalten in: Chemistry of heterocyclic compounds | 2023

von Lapcinska, S. | Arsenyan, P.

2

Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse

enthalten in: Current oncology reports | 2022

von Washington, C. | Moore, K.

3

Imaging PARP with [18F]rucaparib in pancreatic cancer models

enthalten in: European journal of nuclear medicine & molecular imaging | 2022

von Chan, C. | Chen, Z. | Destro, G. | +9

4

Appropriate Selection of PARP Inhibitors in Ovarian Cancer

enthalten in: Current treatment options in oncology | 2022

von Smith, M. | Pothuri, B.

5

Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Green, M. | Ma, S. | Goble, S. | +6

6

A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Liao, M. | Jeziorski, K. | Tomaszewska-Kiecana, M. | +12

7

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Grechko, N. | Skarbova, V. | Tomaszewska-Kiecana, M. | +10

8

Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations

enthalten in: American journal of translational research | 2021

von McFarland, T. | Kessel, A. | Swami, U. | +1

9

PARP inhibitors in prostate cancer : practical guidance for busy clinicians

enthalten in: Clinical advances in hematology & oncology : H&O | 2020

von VanderWeele, D. | Hussain, M.

10

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2019

von Liao, M. | Watkins, S. | Nash, E. | +10